Arbutus reports second quarter 2024 financial results and provides corporate update

End-of-treatment data presented at the easl congress from two phase 2a clinical trials supports advancing imdusiran as a potential cornerstone in a hbv functional cure treatment regimen

ABUS Ratings Summary

ABUS Quant Ranking